Rubicon Filter
This article was originally published in The Gray Sheet
Executive Summary
Embolic protection device indication for use in saphenous vein grafts will be sought using data from a conventional, single-device U.S. study, expected to begin early in 2005, Rubicon Medical says. Initial plans for a joint, randomized RULE-SVG trial with Boston Scientific's Taxus Liberté paclitaxel-eluting stent have been scrapped to ensure "fewer delays and complexities" following FDA feedback, the firm explains (1"The Gray Sheet" Aug. 23, 2004, In Brief). Separately, Rubicon has finalized a license for SurModics' hydrophilic coating to enhance filter deliverability...